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Abstract
Background
Recent studies suggest a paradoxical association between smoking status and clinical out-
come after intravenous thrombolysis (IVT). Little is known about relationship between smok-
ing and stroke outcome after endovascular treatment (EVT).
Methods
We analyzed data of all stroke patients treated with EVT at the tertiary stroke centre of
Berne between January 2005 and December 2015. Using uni- and multivariate modeling,
we assessed whether smoking was independently associated with excellent clinical out-
come (modified Rankin Scale (mRS) 0–1) and mortality at 3 months. In addition, we
also measured the occurrence of symptomatic intracranial hemorrhage (sICH) and
recanalization.
Results
Of 935 patients, 204 (21.8%) were smokers. They were younger (60.5 vs. 70.1 years of age,
p<0.001), more often male (60.8% vs. 52.5%, p = 0.036), had less often from hypertension
(56.4% vs. 69.6%, p<0.001) and were less often treated with antithrombotics (35.3% vs.
47.7%, p = 0.004) as compared to nonsmokers. In univariate analyses, smokers had higher
rates of excellent clinical outcome (39.1% vs. 23.1%, p<0.001) and arterial recanalization
(85.6% vs. 79.4%, p = 0.048), whereas mortality was lower (15.6% vs. 25%, p = 0.006) and
frequency of sICH similar (4.4% vs. 4.1%, p = 0.86). After correcting for confounders, smok-
ing still independently predicted excellent clinical outcome (OR 1.758, 95% CI 1.206–2.562;
p<0.001).
Conclusion
Smoking in stroke patients may be a predictor of excellent clinical outcome after EVT. How-
ever, these data must not be misinterpreted as beneficial effect of smoking due to the
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Introduction
Smoking is an independent risk factor for ischemic stroke especially in younger people.[1] The
World Health Organization (WHO) estimates that smoking causes about six million deaths
worldwide per year, with increasing incidences especially in developing countries.[2] Though
detrimental effects on vascular health, recent studies report better clinical outcome in smokers
treated with thrombolysis, which is termed as “smoking paradox”. It was first described in
patients with myocardial infarction undergoing intravenous thrombolysis (IVT).[3, 4] Similar
associations have also been reported for smoking, favorable 3-month outcome and recanaliza-
tion in stroke patients treated with IVT.[5] Little is known about relationship between smok-
ing status and stroke outcome after endovascular treatment (EVT), which is increasingly
preferred for treatment of severe strokes with large artery occlusion.[6–9]
Methods
This study was based on the Bernese stroke center database, a systematic prospective registry
of consecutive patients with ischemic stroke treated at the Stroke Center of University Hospital
of Berne, Switzerland. It was approved by the Local Ethics Committee Bern. For this study, we
analyzed all stroke patients who underwent EVT (mechanical thrombectomy and/or intraarte-
rial thrombolysis (IAT) with urokinase) between January 2005 and December 2015. The fol-
lowing variables and stroke risk factors were prospectively collected as defined previously:[10–
12] age, sex, smoking status, antithrombotic medication at stroke onset, diabetes mellitus,
hypertension, hypercholesterolemia, functional independence before stroke (according to
modified Rankin Scale (mRS)), stroke etiology according to the Trial of ORG 10172 in Acute
Stroke Treatment (TOAST) criteria, stroke onset-to-treatment time as well as blood pressure
and blood glucose level obtained on admission. Patients were classified as smokers when they
reported active cigarette use. Severity of the neurological deficit was assessed by a stroke neu-
rologist at admission by using the National Institutes of Health Stroke Scale (NIHSS) score.
[13] All patients underwent immediate brain imaging by magnetic resonance imaging (MRI)
or computer tomography (CT). We performed EVT according to international and institu-
tional guidelines as described previously. Patients were treated with intra-arterial urokinase,
mechanical interventions, or both. Patients within time window of 3 to 4.5 hours were addi-
tionally treated with IVT.[14–16] Vessel occlusion and collateral supply was monitored with
conventional angiography by an interventional neuroradiologist.[17, 18] Localization of arte-
rial occlusion was categorized depending on size as large vessel (internal carotid artery includ-
ing carotid-T) vs. medium vessel occlusion (e.g. M1-segment of middle cerebral artery and
basilar artery). Collaterals were classified as poor, if none or minimal leptomeningeal anasto-
moses were visualized and no or minimal filling of the occluded vessel territory was seen, and
good, if leptomeningeal anastomoses filled the occluded vessel territory by more than half.[17,
18] All patients treated with EVT were admitted to intermediate or intensive care unit or
stroke unit for at least 24 hours. All patients underwent brain imaging with MRI or CT 24
hours after intervention and in any case of clinical deterioration. Symptomatic intracranial
hemorrhage (sICH) was defined according to ECASS II criteria.[19] Status of recanalization
Impact of smoking on stroke outcome after endovascular treatment
PLOS ONE | https://doi.org/10.1371/journal.pone.0194652 May 2, 2018 2 / 11
served on scientific advisory boards for Bayer,
Boehringer-Ingelheim, BMS/Pfizer, Biogen, Merck
and Novartis. The other authors have declared that
no competing interests exist. This does not alter
our adherence to PLOS ONE policies on sharing
data and materials.
was assessed immediately after EVT by using the Thrombolysis in Myocardial infarction
(TIMI) score on angiography.[20, 21] Partial or complete recanalization (TIMI scores 2 and 3)
were classified as successful recanalization.[22–24] Primary endpoints were excellent clinical
outcome at 3 months after stroke (mRS 0 or 1), death within 3 months (mRS 6) and the occur-
rence of sICH. Secondary endpoint was the frequency of successful recanalization after EVT.
The endpoints were prospectively assessed during hospital stay and/or 3-month outpatient
visits.
Statistical analyses
We compared demographic and baseline characteristics between smokers and nonsmokers by
using Pearson’s chi-squared test for categorial variables and two-tailed t-test for continuous
variables (or Mann-Whitney U test for skewed distribution). The independent effect of smok-
ing status on endpoints was assessed in multivariate analyses using blockwise regression
model. Multivariable adjustment was applied for significant baseline differences between
smokers and nonsmokers. Level of significance was set to p < 0.05. Furthermore, we per-
formed subgroup analyses for patients treated with mechanical thrombectomy only and for
those undergoing intra-arterial thrombolysis (IAT) with urokinase (± mechanical thrombect-
omy), respectively. The level of statistical significance was set to 0.05. Statistical analysis was
made using the SPSS Version 21.0.
Results
Baseline characteristics
A total of 935 patients were eligible for this study. Of these, 204 (21.8%) were current smokers.
Thrombolysis with IAT was performed in 405 (43.3%) patients, while 285 (30.5%) underwent
mechanical thrombectomy only and 245 (26.2%) were treated with intra-arterial urokinase in
combination with intravenous alteplase. The main baseline characteristics of the 2 groups are
detailed in Table 1. Compared with nonsmokers, smokers were younger and more often male.
They suffered less often from arterial hypertension, more often from hypercholesterolemia
and were less often treated with antithrombotics. On admission, NIHSS and systolic blood
pressure were significantly lower in smokers. Large-artery atherosclerosis was more often the
underlying stroke reason in smokers, whereas cardioembolism was the leading stroke cause in
nonsmokers. Baseline imaging revealed more often an occlusion of large arteries in smokers
than in the counterpart. In analogy, pure mechanical thrombectomy was more often per-
formed in smokers, whereas nonsmokers underwent more often IAT.
Outcomes
Outcomes are summarized in Fig 1. At 3 months, smokers showed significantly higher rates of
excellent clinical outcome and lower mortality rates as compared to nonsmokers (39.1% vs.
23.1%, p< 0.001 and 15.6% vs. 25%, p = 0.006, respectively), whereas the risk of sICH was
comparable in both groups (4.4% vs. 4.1%, p = 0.006). The frequency of successful recanaliza-
tion was higher in smokers than in nonsmokers (85.6% vs. 79.4%, p = 0.048). In line with this,
stroke severity measured by NIHSS at 24 hours after treatment was significantly lower in
smokers as compared to the counterpart (7.0 vs. 10.0, p = 0.005).
Details of multivariate analyses are shown in S1 Table. Adjustment was made for following
variables with statistically significant differences at baseline: age, sex, NIHSS and systolic blood
pressure at admission, smoking status and antithrombotics before stroke onset, stroke etiology
according to TOAST criteria, localization of occluded vessel and hypercholesterolemia.
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Table 1. Baseline characteristics in smoking and nonsmoking stroke patients.
All Patients
(n = 935)
Smokers
(n = 204)
Nonsmokers
(n = 731)
p
Mean age ± SD, years 68 ± 13.9 60.5 ± 12.1 70.1 ± 13.7 <0.001
Male gender 508/935 (54,3) 124/204 (60.8) 384/731 (52.5) 0.036
Diabetes mellitus 152/935 (16.3) 26/204 (12.7) 126/731 (17.2) 0.124
Arterial hypertension 624/935 (66.7) 115/204 (56.4) 509/731 (69.6) <0.001
Hypercholesterolemia 527/925 (57) 128/203 (63.1) 399/722 (55.3) 0.048
Antithrombotic pretreatment 342/761 (44.9) 60/170 (35.3) 282/591 (47.7) 0.004
Functional independency before stroke (mRS 0–2) 890/934 (95.3) 198/204 (97.1) 692/730 (94.8) 0.177
NIHSS at admission, median (IQR) 15.0 (10–19) 14.0 (9–18) 15.0 (10–20) 0.024
Mean systolic blood pressure/mmHg ± SD 154 ± 27.5 149 ± 26.8 156 ± 27.5 0.006
Mean glucose/mmol/l ± SD 7.18 ± 2.29 6.87 ± 2.16 7.26 ± 2.36 0.062
Median time to treatment/min (IQR) 274 (213–355) 280 (224–359) 273 (210–351) 0.436
Stroke etiology (TOAST) <0.001
- large artery atherosclerosis 139/932 (14.9) 49/203 (24.1) 90/729 (12.3)
- cardioembolic 409/932 (43.9) 60/203 (29.6) 349/729 (47.9)
- others, n (%) 45/932 (4.8) 10/203 (4.9) 35/729 (4.8)
- undetermined, n (%) 339/932 (36.4) 84/203 (41.4) 255/729 (35)
Localization of arterial occlusion 0.01
- large vessel, n (%) 200/817 (24.5) 54/168 (32.1) 146/649 (22.5)
- medium vessel, n (%) 617/817 (75.5) 114/168 (67.9) 503/649 (77.5)
Good collaterals, n (%) 302/792 (38.1) 62/158 (39.2) 240/634 (37.9) 0.828
Type of treatment 0.031
- IAT 405/935 (43.3) 73/204 (35.8) 332/731 (45.4)
- IAT + IVT 245/935 (26.2) 56/204 (27.5) 189/731 (25.9)
- mechanical thrombectomy 285/935 (30.5) 75/204 (36.8) 210/731 (28.7)
Results are expressed in n/N (%) unless otherwise denoted
IA denotes intra-arterial thrombolysis with urokinase, IQR interquartile range, IV intravenous thrombolysis with alteplase, min minute, mRS modified Rankin Scale,
NIHSS National Institutes of Health Stroke Scale, SD standard deviation, TOAST Trial of Org 10172 in Acute Stroke Treatment.
https://doi.org/10.1371/journal.pone.0194652.t001
Fig 1. Outcomes in smoking vs. non-smoking stroke patients after endovascular treatment. Results are expressed in n/N (%). CI confidence interval, mRS modified
Rankin Scale, OR odds ratio, sICH symptomatic intracranial hemorrhage. 1 adjusted for age, sex, NIHSS on admission, systolic blood pressure on admission, stroke
etiology, localization of occluded vessel, hypercholesterolemia and use of antithrombotic pretreatment.
https://doi.org/10.1371/journal.pone.0194652.g001
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Multivariate analyses revealed current smoking status as an independent predictor of excellent
clinical outcome (Odds ratio (OR) 1.758, 95% confidence interval (95% CI) 1.206–2.562,
p< 0.001) together with age and baseline NIHSS score. Mortality at 3 months was also inde-
pendently associated with age and baseline NIHSS, but not with smoking status (OR 0.868,
95% CI 0.531–1.420, p = 0.573). None of the variables was independently associated with
sICH, this was also true for smoking status (OR 1.027, 95% CI 0.478–2.206, p = 0.945). Hyper-
cholesterolemia and large vessel occlusion were identified as independent predictors of recana-
lization after EVT, whereas no association was observed with smoking status (OR 1.344, 95%
CI 0.832–2.173, p = 0.227).
We additionally performed subgroup analyses with focus on patients undergoing mechani-
cal thrombectomy only (n = 285) and those treated with intra-arterial urokinase (n = 405).
Logistic regression analyses included age, NIHSS at admission, large vessel occlusion and
smoking status as covariates. The results are shown in Tables 2 and 3. Smokers treated with
pure mechanical thrombectomy had significantly higher rates of excellent clinical outcome at
3 months as compared to nonsmokers (37.1% vs. 19%, p = 0.002), while no differences were
detected regarding mortality at 3 months, sICH and recanalization. Logistic regression analy-
sis revealed an independent association for age and NIHSS (OR 0.199, 95% CI 0.942–0.990,
p = 0.006 and OR 0.856, 95% CI 0.803–0.914, p< 0.001, respectively), but not for smoking
(OR 1.604, 95% CI 0.724–3.551, p = 0.244). Smokers treated with intra-arterial urokinase
reached also higher rates of excellent clinical outcome (39.4% vs. 20.9%, p = 0.001) and tended
to lower mortality risk (15.5% vs. 24.2%, p = 0.058). The following variables were strongly
associated with excellent clinical outcome: age (OR 0.973, 95% CI 0.954–0.991, p = 0.004),
NIHSS (OR 0.910, 95% CI 0.872–0.950, p < 0.001), smoking (OR 2.412, 95% CI 1.245–4.671,
p = 0.009).
Table 2. Outcomes after mechanical thrombectomy only in smoking vs. nonsmoking patients.
All patients
(n = 285)
Smokers
(n = 75)
Nonsmokers
(n = 210)
p
Excellent clinical outcome (mRS 0–1) 63/265 (23.8) 26/70 (37.1) 37/195 (19) 0.002
Death 68/265 (25.7) 14/70 (20) 54/195 (27.7) 0.206
sICH 13/284 (4.6) 6/75 (8) 7/209 (3.3) 0.098
Successful recanalization 235/277 (84.8) 64/74 (86.5) 171/203 (84.2) 0.644
Results are expressed in n/N (%)
mRS denotes modified Rankin Scale, NIHSS National Institutes of Health Stroke Scale and sICH, symptomatic intracranial hemorrhage
https://doi.org/10.1371/journal.pone.0194652.t002
Table 3. Outcomes after IAT with urokinase in smoking vs. nonsmoking patients.
All patients
(n = 405)
Smokers
(n = 73)
Nonsmokers
(n = 332)
p
Excellent clinical outcome (mRS 0–1) 96/396 (24.2) 28/71 (39.4) 68/325 (20.9) 0.001
Death 96/396 (24.2) 11/71 (15.5) 85/325 (26.2) 0.058
sICH 20/402 (5) 2/73 (2.7) 18/329 (5.5) 0.332
Successful recanalization 288/402 (71.6) 53/71 (74.6) 235/331 (71) 0.536
Results are expressed in n/N (%)
mRS denotes modified Rankin Scale, NIHSS National Institutes of Health Stroke Scale and sICH, symptomatic intracranial hemorrhage
https://doi.org/10.1371/journal.pone.0194652.t003
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Discussion
This study suggests that current smoking may be an independent predictor of excellent clinical
outcome in ischemic stroke treated with EVT. To date, many studies investigated the relation-
ship between smoking status and outcome after IVT in stroke patients and reported conflicting
results.[5, 25–28] However, data on EVT are scarce. Meseguer and colleagues showed that
intra-arterial administration of rtPA independently predicts arterial recanalization in smokers,
but had no significant impact on clinical endpoints such as favorable outcome, mortality or
sICH.[29] However, the cohort size was rather small as compared to our study (227 vs. 935
patients). We are not aware of further studies assessing the relationship between smoking and
stroke outcome after EVT.
Considering differences in baseline characteristics is essential for discussion of “smoking
paradox” in stroke patients. In line with literature, smokers in our study were significantly
younger, more likely to be male and suffered less often from atrial fibrillation and arterial
hypertension than nonsmokers.[5, 26, 27, 29] These imbalances could partially explain the
better clinical outcomes in favor of smokers, as older age and male gender have been
shown to be associated with worse clinical outcomes.[30–33] In line with this, Hussein
et al. suggested that smoking paradox may be mainly related to differences in age.[25] In
addition, Tong et al. recently reported that noncardioembolic stroke may be independently
related to good outcome in smoking patients treated with IVT.[34] Cardioembolism was
the underlying stroke reason for almost every second non-smoking patient in our study.
Cardioembolic stroke due to arterial fibrillation is considered to be an independent risk
factor for large territorial infarcts, hemorrhagic transformation and unfavorable outcome
after stroke.[35–37] Furthermore, stroke severity at admission (measured by NIHSS)
tended to be lower in smokers which may also have contributed to differences in outcome.
[38, 39]
Mechanical thrombectomy was more often used in smokers (36.8% vs. 28.7%), whereas
IAT was the preferred treatment in non-smokers (45.4% vs. 35.8%). We assume, that these dif-
ferences in treatment may primarily be related to higher proportion of large vessel occlusions
in smokers.
The relationship between favorable outcome and smoking status after thrombolysis has
also been reported in stroke patients treated with IVT.[5] Other studies could not detect an
association between outcome and smoking habits though higher rates of recanalization in
smokers.[26, 29] The conflicting results may be related to differences in study size as the num-
ber of included patients reported in studies range from 94 to 5383.[5, 25] Furthermore, loca-
tion of vessel occlusion may have played an important role. Smoking patients suffered more
frequently from large artery occlusion, which was independently associated with recanaliza-
tion in this study. The association between higher recanalization rates and proximal vessel
occlusion in EVT has already been reported in a large cohort with anterior circulation stroke.
[40] In contrary, large vessel occlusion is inversely related to recanalization and outcome in
stroke patients treated with IVT.[41–43] Hypercholesterolemia was another independent pre-
dictor of recanalization in our study. Vanacker et al. reported an independent association
between hypercholesterolemia and spontaneous recanalization in patients with ischemic
stroke.[44] Galimanis et al. also observed higher recanalization rates in stroke patients with
hypercholesterolemia after EVT.[40] Antioxidant effects of lipids or lower rates of concomi-
tant infections were discussed as potential explanations.[45, 46] Pleiotropic effects of statins in
these patients may also be of importance.[47]
An increased efficacy of rtPA in smokers has been reported before with respect to different
rates of recanalization depending on thrombus composition.[28, 29] Smoking patients are
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assumed to have an increased hematocrit, platelet activation and aggregation, vasoconstriction
and circulating fibrinogen.[48–50] Thus, smokers may have more thrombogenic than athero-
genic vessel occlusion, whereas nonsmokers may have more likely vessel occlusion due to rup-
tured or ulcerated plaque with platelet-rich clot.[51] However, we could not prove a strong
association between smoking status and recanalization after EVT. Ali et al. reported a lower
in-hospital mortality in smoking stroke patients irrespective of thrombolysis and discussed a
greater susceptibility of thrombi to therapeutic as well as to spontaneous thrombolysis due to
the different thrombus compositions.[51] Our subgroup analyses suggest that smoking may
have a greater impact on clinical outcome in patients treated with IA urokinase than in those
treated with pure mechanical thrombectomy. This finding could be in line with the abovemen-
tioned hypothesis of increased susceptibility of thrombi to fibrinolytic drugs in smokers. Mor-
tality among smokers was also lower in our study, but the association lost significance after
adjusting for confounders. Smokers may be supposed to have a better cerebral collateral supply
as a further explanation for paradoxical association with clinical outcome, but collateral supply
did not differ between groups in our study. Still, smokers may be better preconditioned on
ischemia due to increased plasma levels of carbon monoxide and episodic hypoxia.[52] Smok-
ing status had no impact on risk of sICH after treatment in this study, which is in line with lit-
erature.[5, 27, 29]
The main strength of this study is the large cohort size, which allows adjustment for poten-
tial confounders and decreases the odds for false-positive results. This is to our best knowl-
edge the largest study assessing relationship between EVT and smoking status. Furthermore,
data quality was high as both clinical and radiological data were systematically and prospec-
tively collected at baseline and during 3-month follow-up by certified neurologists and neu-
roradiologists. In addition, we aimed at comprehensive data collection including location of
vessel occlusion, recanalization and collateral supply, which were not considered in former
studies.
We are aware of several limitations. First, this was an observational study with an inherent
risk of treatment bias which may not be completely removed though multivariate model. As
consequence, a firm conclusion about causality between smoking and outcome is prohibited.
Second, we did not record quantity of smoking exposure, leading to a heterogeneity in our
smoking cohort and hindering a differentiation of heavy vs. mild smokers. A dose-dependent
relation between smoking and blood viscosity with increase of plasma-fibrinogen level has
been reported.[53] Third, there may be some hidden confounders which were not included in
our study such as mode and intensity of rehabilitation, socio-economic status and medical
complications. Furthermore we did not adjust for other prognostic factors such as time to
recanalization or radiological scores of stroke severity. Fourth, current guidelines recommend
the use of TICI (Thrombolysis In Cerebral Infarction) study for assessment of arterial recanali-
zation.[54] We used TIMI scale for historical reasons, because recommendation for TICI was
published towards the end of our study period. Fifth data were collected over ten years during
which a great evolution on stroke treatment was taking place. Especially recanalization tech-
niques and acute stroke care like stroke unit care and early rehabilitation might influence out-
come in stroke patients. Nevertheless endovascular stroke therapy has a long tradition in our
center and has been systematically performed. The publication of the major randomised con-
trolled trials on EVT did not change our treatment approach. Furthermore the main question
was to determine differences between smokers and nonsmokers. Those two groups were
treated with same procedures and were affected in a similar way of mentioned changes.
Finally, we did not measure changes in smoking habits (e.g. cessation of smoking) after stroke
which may also have influenced the 3-month outcome.
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Conclusion
In summary, our data indicate that smoking in stroke patients may be independently associ-
ated with excellent clinical outcome after EVT. Though strong relationship in multivariable
analyses, significant differences in baseline characteristics still needed to be considered
together with different pathophysiological mechanisms. A conclusion on causality is not reli-
able due to the observational study design. Thus, these data must not be misinterpreted as a
beneficial effect of smoking. In view of deleterious effects of cigarette smoking on cardiovascu-
lar health, cessation of smoking should still be strongly recommended for both primary and
secondary stroke prevention
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S1 Table. Blockwise-backwards regression analyses for favorable outcome, death after 3
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